Preterm children at greater risk of astigmatism

Article

Children born before week 35 of pregnancy have a greater risk of developing refractive errors than children born at full term, according to a report published in the November 2006 issue of Archives of Ophthalmology.

Children born before week 35 of pregnancy have a greater risk of developing refractive errors than children born at full term, according to a report published in the November 2006 issue of Archives of Ophthalmology.

Eva Larsson, MD from Uppsala University Hospital, Sweden, conducted a study to investigate the development of astigmatism and anisometropia of 1 diopter (D) or more in 198 preterm children at six months, 2.5 and 10 years of age.

The amount and prevalence of astigmatism declined between six months and 2.5 years of age and stabilised. A total of 108 children had astigmatism at six months, 54 at 2.5 years and 41 at 10 years. No difference was found in the course of astigmatism at different ages in relation to the stage of retinopathy or prematurity. Anisometropia did increase but its prevalence was unchanged.

Using multiple regression analyses, the researchers found that astigmatism of 1 D or more at 2.5 years of age and cryotreated severe retinopathy of prematurity were risk factors for astigmatism at 10 years of age and that anisometropia of 2 D or more at 2.5 years of age was a risk factor for anisometropia at 10 years of age.

Dr Larsson noted that the development of astigmatism and anisometropia show a similar course, regardless of the stage of retinopathy of prematurity and that refraction measurements at 2.5 years of age can be used as a predictor of later refractive errors.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.